Thrombotic Markers in Plasma as Predictors of Response in Rheumatoid Arthritis Patients Treated with Baricitinib – Pilot Observation
Open Access
- 1 January 2025
- journal article
- Published by Walter de Gruyter GmbH in Archivum Immunologiae et Therapiae Experimentalis
- Vol. 73 (1)
Abstract
Both disease and treatment carry the risk of thrombotic events in patients with rheumatoid arthritis (RA). This pilot study aimed to assess changes in thrombotic markers in plasma and their potential role as predictors of response during early baricitinib treatment. The concentrations of antithrombin III (ATIII) activity, D-dimer (DD), fibrinogen, and homocysteine (HCY) were evaluated in RA subjects before and 3 months after the treatment. At baseline, the RA group had higher DD (1472.3 ± 349.2) and fibrinogen (410.4 ± 29.5) compared with healthy controls (HC; 450.3 ± 54.5; p = 0.0002 and 334.9 ± 19.2; p = 0.04, respectively). with no differences in ATIII and HCY. After 3 months, we observed a significant increase in HCY (10.7 ± 0.6 vs. 9.1 ± 0.5; p = 0.018) and ATIII (119.7 ± 2.7 vs . 110.4 ± 3.2; p = 0.004), the latter correlated negatively with disease activity score 28 (DAS28; r = −0686, p < 0.002). After 3 months of baricitinib therapy, the patients were divided into moderate responders (MR) and good responders (GR) groups according to EULAR criteria. At baseline, MR had higher DD (1639.2 ± 550.5 vs . 450.3 ± 54.5; p < 0.0001) and lower ATIII (105.3 ± 3.6 vs . 115.1 ± 2.7; p = 0.043) compared with HC. Thrombotic parameters in the first 3 months of baricitinib treatment were mostly in line with current findings concerning the RA population. Increased levels of DD together with low ATIII concentrations seem to predispose to a moderate response to baricitinib treatment.Keywords
This publication has 41 references indexed in Scilit:
- Tofacitinib Affects M1-like and M2-like Polarization and Tissue Factor Expression in Macrophages of Healthy Donors and IBD PatientsInflammatory Bowel Diseases, 2023
- JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte–endothelial proadhesive interactionsJournal of Thrombosis and Haemostasis, 2023
- Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical StudiesRheumatology and Therapy, 2023
- High plasma homocysteine level is associated with increased prevalence of the non-remission state in rheumatoid arthritis: Findings from the KURAMA cohortModern Rheumatology, 2022
- FABP4 activates the JAK2/STAT2 pathway via Rap1a in the homocysteine-induced macrophage inflammatory response in ApoE mice atherosclerosisLaboratory Investigation, 2021
- The Rheumatoid Arthritis-Associated CitrullinomeCell Chemical Biology, 2018
- Can we predict thrombotic tendency in rheumatoid arthritis? A thromboelastographic analysis (with ROTEM)Clinical Rheumatology, 2018
- Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkersNature Reviews Rheumatology, 2016
- Antithrombin III associated with fibrinogen predicts the risk of cerebral ischemic strokeClinical Neurology and Neurosurgery, 2011
- The Disease Activity Score and the EULAR Response CriteriaRheumatic Disease Clinics of North America, 2009